Literature DB >> 7788123

Prevalence of depression after stroke: the Perth Community Stroke Study.

P W Burvill1, G A Johnson, K D Jamrozik, C S Anderson, E G Stewart-Wynne, T M Chakera.   

Abstract

BACKGROUND: The Perth Community Stroke Study (PCSS) was a population-based study of the incidence, cause, and outcome of acute stroke.
METHOD: Subjects from the study were assessed initially, by examination and interview, and at four- and 12-month follow-ups to determine differences in prevalence of depression between the sexes and between patients with first-ever and recurrent strokes.
RESULTS: The prevalence of depressive illness four months after stroke in 294 patients from the PCSS was 23% (18-28%), 15% (11-19%) major depression and 8% (5-11%) minor depression. There were no significant differences between the sexes or between patients with first-ever and recurrent strokes. With a non-hierarchic approach to diagnosis of those with depression, 26% of men and 39% of women had an associated anxiety disorder, mainly agoraphobia. Nine per cent of male and 13% of female patients interviewed had evidence of depression at the time of the stroke. Twelve months after stroke 56% of the men were still depressed (40% major and 16% minor), as were 30% of the women (12% major and 18% minor).
CONCLUSION: The prevalence of depression after stroke was comparable with that reported from other studies, and considerably less than that reported from in-patient and rehabilitation units.

Entities:  

Mesh:

Year:  1995        PMID: 7788123     DOI: 10.1192/bjp.166.3.320

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  44 in total

1.  Patterns of change in depression after stroke.

Authors:  Glenn V Ostir; Ivonne-M Berges; Allison Ottenbacher; Kenneth J Ottenbacher
Journal:  J Am Geriatr Soc       Date:  2011-01-28       Impact factor: 5.562

Review 2.  Poststroke depression: a review.

Authors:  Robert G Robinson; Gianfranco Spalletta
Journal:  Can J Psychiatry       Date:  2010-06       Impact factor: 4.356

Review 3.  [Post-stroke depression: clinical aspects, epidemiology, therapy, and pathophysiology].

Authors:  G Kronenberg; J Katchanov; M Endres
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

Review 4.  The neuroanatomical model of post-stroke depression: towards a change of focus?

Authors:  Micaela Santos; Enikö Kövari; Gabriel Gold; Vasilis P Bozikas; Patrick R Hof; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  J Neurol Sci       Date:  2009-03-04       Impact factor: 3.181

Review 5.  The impact of vascular burden on late-life depression.

Authors:  Micaela Santos; Enikö Kövari; Patrick R Hof; Gabriel Gold; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  Brain Res Rev       Date:  2009-09-08

Review 6.  Developments in treating the nonmotor symptoms of stroke.

Authors:  Argye E Hillis
Journal:  Expert Rev Neurother       Date:  2020-05-12       Impact factor: 4.618

Review 7.  Defining and quantifying coping strategies after stroke: a review.

Authors:  C Donnellan; D Hevey; A Hickey; D O'Neill
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11       Impact factor: 10.154

8.  Association between inflammatory cytokines and the risk of post-stroke depression, and the effect of depression on outcomes of patients with ischemic stroke in a 2-year prospective study.

Authors:  Jian-Tong Jiao; Chao Cheng; Ying-Jun Ma; Jin Huang; Min-Chao Dai; Chen Jiang; Cheng Wang; Jun-Fei Shao
Journal:  Exp Ther Med       Date:  2016-06-30       Impact factor: 2.447

Review 9.  Biological risk factors for late life depression.

Authors:  Henning Tiemeier
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

10.  Multisystem physiological dysfunction is associated with depressive symptoms in a population-based sample of older adults.

Authors:  Roni W Kobrosly; Christopher L Seplaki; Deborah A Cory-Slechta; Jan Moynihan; Edwin van Wijngaarden
Journal:  Int J Geriatr Psychiatry       Date:  2012-09-07       Impact factor: 3.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.